Alexion Pharmaceuticals (NASDAQ:ALXN) Cut to Sell at BidaskClub

BidaskClub lowered shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning, BidAskClub reports.

A number of other analysts have also commented on the company. Citigroup cut their price target on Alexion Pharmaceuticals from $180.00 to $165.00 and set a buy rating on the stock in a report on Thursday, May 23rd. Raymond James boosted their price target on Alexion Pharmaceuticals from $164.00 to $168.00 and gave the company an outperform rating in a report on Thursday, July 25th. ValuEngine lowered Alexion Pharmaceuticals from a hold rating to a sell rating in a report on Saturday, July 6th. Wedbush started coverage on Alexion Pharmaceuticals in a report on Wednesday, May 22nd. They issued an outperform rating and a $173.00 price target on the stock. Finally, Zacks Investment Research lowered Alexion Pharmaceuticals from a buy rating to a hold rating in a report on Friday, May 24th. Two analysts have rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals has an average rating of Buy and an average price target of $162.88.

ALXN stock traded down $2.57 during midday trading on Wednesday, hitting $112.34. 1,652,976 shares of the company’s stock were exchanged, compared to its average volume of 2,006,500. The stock’s fifty day moving average is $123.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.56 and a current ratio of 4.04. The company has a market cap of $25.40 billion, a P/E ratio of 15.84, a PEG ratio of 1.08 and a beta of 1.65. Alexion Pharmaceuticals has a one year low of $92.56 and a one year high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.51. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The company’s revenue for the quarter was up 15.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.07 earnings per share. On average, analysts predict that Alexion Pharmaceuticals will post 9 earnings per share for the current fiscal year.

In related news, Director Bros. Advisors Lp Baker sold 123,489 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $126.53, for a total transaction of $15,625,063.17. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Indrani Lall Franchini sold 4,500 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $132.78, for a total value of $597,510.00. Following the sale, the executive vice president now owns 29,627 shares in the company, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. Insiders have sold 428,567 shares of company stock worth $53,420,869 in the last quarter. 4.08% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Whittier Trust Co. raised its holdings in Alexion Pharmaceuticals by 20.4% during the first quarter. Whittier Trust Co. now owns 472 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 80 shares in the last quarter. Avestar Capital LLC increased its position in Alexion Pharmaceuticals by 10.7% during the first quarter. Avestar Capital LLC now owns 836 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 81 shares during the last quarter. We Are One Seven LLC increased its position in Alexion Pharmaceuticals by 5.7% during the second quarter. We Are One Seven LLC now owns 1,586 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 86 shares during the last quarter. Institutional & Family Asset Management LLC increased its position in Alexion Pharmaceuticals by 39.5% during the first quarter. Institutional & Family Asset Management LLC now owns 307 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 87 shares during the last quarter. Finally, YorkBridge Wealth Partners LLC increased its position in Alexion Pharmaceuticals by 15.4% during the first quarter. YorkBridge Wealth Partners LLC now owns 696 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 93 shares during the last quarter. Institutional investors and hedge funds own 94.74% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: Oversold

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.